Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8281 to 8295 of 8905 results

  1. Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)

    This evidence summary has been updated and replaced by the NICE guideline CG178 (published February 2014).

    Withdrawn advice

  2. Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin (ESNM44)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Withdrawn advice

  3. Induction of labour: misoprostol vaginal delivery system (ESNM38)

    We withdrew this evidence summary in May 2021 because the manufacturer has discontinued the product.

    Withdrawn advice

  4. Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)

    This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.

    Withdrawn advice

  5. Type 2 diabetes: insulin degludec (ESNM4)

    This evidence summary has been updated and replaced by NICE advice ESNM25.

    Withdrawn advice

  6. Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  7. Psoriatic arthritis in adults: certolizumab pegol (ESNM42)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.

    Withdrawn advice

  8. Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Withdrawn advice

  9. Health app: GDm-Health for people with gestational diabetes (MIB131)

    This health app briefing on GDm-Health for people with gestational diabetes has been withdrawn.

    Withdrawn advice

  10. Point-of-care creatinine tests before contrast-enhanced imaging (MIB136)

    This advice has been replaced by NICE HealthTech guidance 530.

    Withdrawn advice

  11. Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection (MIB247)

    This advice has been updated and replaced by NICE guideline NG199.

    Withdrawn advice

  12. GaitSmart assessment and vGym personalised exercise rehabilitation programme for people with gait and mobility issues (MIB283)

    This medtech innovation briefing has been replaced by NICE healthtech guidance 716.

    Withdrawn advice

  13. AposHealth for knee osteoarthritis (MIB284)

    This medtech innovation briefing has been updated and replaced by NICE healthtech guidance 671. 

    Withdrawn advice

  14. The Prosigna gene expression profiling assay for assessing long‑term risk of breast cancer recurrence (MIB27)

    This advice has been updated and replaced by NICE diagnostics guidance 34.

    Withdrawn advice

  15. Genedrive MT-RNR1 ID System for detecting single nucleotide polymorphism m.1555A G in newborn babies (MIB290)

    This medtech innovation briefing has been updated and replaced by NICE's early value assessment guidance on Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.

    Withdrawn advice